Hepatitis C - PR Newswire: Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented for First Time at American

PR Newswire: Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented for First Time at American
Belga Direct Press Releases - News Wires KENILWORTH, New Jersey, November 7 /PRNewswire/ -- - Final Results of PEGINTRON(R) Combination Therapy Studies Also PresentedImportant new data on Schering-Plough's investigational oral development for treating hepatitis C virus (HCV) infection will be presentedfor the first for liver transplant in Europe.HCV Protease Inhibitor (SCH 503034)Oral PresentationsAnti

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Com
Canada NewsWire - Results Reported at American Association for the Study of Liver Diseases (AASLD) Meeting Large Phase II Combination Study Under Way SAN FRANCISCO, Nov. chronically infected with hepatitis Cvirus (HCV) genotype 1 who were nonresponders to therapy, includingpeginterferon combination therapy. HCV genotype 1 is the most common form

Safety and Efficacy of Pegasys Plus Ribavirin in HCV Patients Intolerant or Nonresponsive to Treatment with Pe
HIV and Hepatitis.com - RBV dose reductions also are associated with decreased SVR. Era of Protease Inhibitors for the Treatment of HCV: An Overview of SCH 503034 SCH 503034 is a new, orally administered HCV protease inhibitor that has shown potent

Virological And Histological Features Of Hcv In Patients With Normal Alt: Results Of A Ten Year Propsective Fo
National AIDS Treatment Advocacy Project - histology worsened in 20.8% of anti HCV+ve pts with persistently normal ALT --Neither serum HCV-RNA nor ALT level can reliably

InterMune Sharpens Focus on Key Development Programs and Significantly Strengthens Financial Position
PR NewsWire via Forbes.com - in Cash - - Retains Full Ownership of HCV Protease Inhibitor Program - - Reduces Annual Operating IPF), pirfenidone for IPF, and the hepatitis C virus (HCV) protease inhibitor